Skip to content

Search

Showing results for "mental health aboriginal"

Landmark research hopes to increase survival rates for aggressive childhood cancer

A new combination of drugs could help to increase survival rates with fewer side effects for some children with one of the most aggressive forms of childhood brain cancer.

Researchers to focus on MS inflammation puzzle

The Kids Research Institute Australia researchers will seek to better understand the relationship between antibodies and inflammation in people with multiple sclerosis (MS), thanks to a generous grant from MS Research Australia.

Improving development and learning of children in Western Australia

Discover the EYI Research Profile at The Kids' Institute, showcasing innovative child health research and its impact on young lives.

Five things that may surprise you about type 1 diabetes

Professor Liz Davis reveals five things you might not know about type 1 diabetes.

New drug therapy provides hope for kids with cystic fibrosis

The family of two girls with cystic fibrosis are hopeful after The Kids Research Institute Australia spin-off company, Respirion, receives $20 million in funding to develop a promising new therapy.

Meet Baxter Hutchinson

Baxter Hutchinson was diagnosed with two life-threatening brain tumours a year ago, aged 17. Since then he has undergone surgery, radiotherapy and chemotherapy in his journey to beat the cancer.

Can a simple urine test predict asthma? New study aims to find out

The Kids Research Institute Australia researchers are investigating whether a simple urine test could predict whether young children with wheezing symptoms will go on to develop asthma.

Researchers find new way to deliver ‘smart drugs’ for hard-to-treat diseases

Researchers from Perth’s The Kids Research Institute Australia have developed a world-first screening tool that helps deliver smart drugs into cells to battle hard-to-treat diseases like cancer and Duchenne Muscular Dystrophy.

WA partnership to unlock new antibiotic weapon

The Kids Research Institute Australia and WA pharmaceuticals company Boulos and Cooper have signed a $685,000 agreement to develop what could be the first new class of antibiotics in decades.

UV offers new hope in fight against MS

People at risk of developing multiple sclerosis (MS) have been offered a beacon of hope thanks to research into UV exposure.